Q-omics provides the consensus-scored DEFB118 profile across patient tissues and cancer cell-line models. DEFB118 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DEFB118 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, DEFB118 RNA expression shows 6,420 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where DEFB118 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB118 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB118 survival associations across molecular data types. DEFB118 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB118 RNA expression–survival associations across cancer types. High DEFB118 expression shows unfavorable associations in KIRC, ACC, UCS, UCEC, THYM and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DEFB118 RNA expression.
This table summarizes DEFB118 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DEFB118. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB118 shows lower tumor expression in BRCA and THCA. The BRCA box plot shows higher DEFB118 RNA expression in normal versus tumor tissue (log2 FC = −0.029, t-test p < 0.001).
This table shows molecular features associated with DEFB118 in patient tissues and cancer cell lines. In patient samples, DEFB118 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB118 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OESOPHAGUS.
